Effects of emodin in preclinical models of myocardial injury: a systematic review and meta-analysis
Frontiers in Cardiovascular Medicine · 12.11.2026 · 13
DOI: 10.3389/fcvm.2026.1968777 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 12.11.2026. Verfasst von Shaoyu Chen und 2 weiteren Autor:innen. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Emodin, a plant-derived anthraquinone, has shown cardioprotective potential in animal models, but the evidence is dispersed across small preclinical studies.
Methods
PubMed, CNKI, Embase, and Web of Science were searched from inception to June 18, 2026, for controlled animal studies comparing emodin with vehicle controls in myocardial injury models. Continuous outcomes were pooled using random-effects models and expressed as standardized mean differences (SMDs) with 95% confidence intervals (CIs). Heterogeneity was assessed via I 2 . Leave-one-out analyses assessed robustness, and exploratory subgroup analyses examined heterogeneity. Egger's regression test assessed funnel plot asymmetry for outcomes with at least 10 studies. The protocol was registered with PROSPERO (CRD420261389730).
Results
Sixteen studies involving 262 animals were included. Emodin significantly reduced creatine kinase (CK, SMD = −11.83, 95% CI: −13.78 to −9.87, I 2 = 0%), creatine kinase-MB isoenzyme (CK-MB, SMD = −7.42, 95% CI: −10.05 to −4.78, I 2 = 83.0%), and lactate dehydrogenase (LDH, SMD = −10.03, 95% CI: −15.52 to −4.55, I 2 = 85.5%). Concomitantly, it improved left ventricular ejection fraction (LVEF, SMD = 5.35,95% CI: 2.76 to 7.94, I 2 = 81.0%) and left ventricular shortening fraction (LVSF, SMD = 3.59, 95% CI: 2.54 to 4.63, I 2 = 0%). Pooled effect directions remained unchanged in leave-one-out analyses. Sparse, correlated subgroups prevented reliable attribution of heterogeneity to individual study characteristics. The LVEF funnel plot was asymmetric. Trim-and-fill imputed two studies, after which the pooled LVEF effect was no longer statistically significant (SMD = 3.50, 95% CI: −0.28 to 7.28; P = 0.07).
Conclusions
This study suggests that emodin may reduce markers of myocardial injury and improve cardiac function. However, small sample sizes, risk of bias, and heterogeneity among the included studies limit confidence in these findings. Before clinical studies begin, pharmacokinetic research should clarify how exposure to emodin and its metabolites relates to pharmacodynamic effects. Systematic Review Registration : https://www.crd.york.ac.uk/PROSPERO/view/CRD420261389730 , identifier CRD420261389730.
Zitieren
APA
Chen, S., Zhang, M., & Li, D. (2026). Effects of emodin in preclinical models of myocardial injury: a systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1968777
Vancouver
Chen S, Zhang M, Li D. Effects of emodin in preclinical models of myocardial injury: a systematic review and meta-analysis. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1968777
BibTeX
@article{Chen2026,
author = {Chen, Shaoyu and Zhang, Mengying and Li, Da},
title = {Effects of emodin in preclinical models of myocardial injury: a systematic review and meta-analysis},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1968777}
}
EUVIMED